A Phase 2, Open-label, Randomized Study to Evaluate the Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia
Latest Information Update: 13 Jun 2023
At a glance
- Drugs Momelotinib (Primary)
- Indications Essential thrombocythaemia; Polycythaemia vera
- Focus Therapeutic Use
- Sponsors Gilead Sciences; Sierra Oncology
- 18 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 18 Feb 2014 Status changed from not yet recruiting to recruiting, as per ClinicalTrials.gov record.
- 06 Dec 2013 New trial record